Insight Molecular Diagnostics Price to Free Cash Flow Ratio 2014-2026 | IMDX
Historical price to free cash flow ratio values for Insight Molecular Diagnostics (IMDX) since 2014.
| Insight Molecular Diagnostics Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-12 | 5.61 | 23.38 | |
| 2026-03-31 | 3.28 | $0.24 | 13.67 |
| 2025-12-31 | 7.50 | 0 | 0.00 |
| 2025-09-30 | 3.32 | $-1.06 | 0.00 |
| 2025-06-30 | 3.02 | $-1.24 | 0.00 |
| 2025-03-31 | 3.06 | $-1.40 | 0.00 |
| 2024-12-31 | 2.38 | $-1.62 | 0.00 |
| 2024-09-30 | 2.85 | $-1.93 | 0.00 |
| 2024-06-30 | 2.95 | $-1.96 | 0.00 |
| 2024-03-31 | 2.93 | $-2.11 | 0.00 |
| 2023-12-31 | 2.50 | $-3.04 | 0.00 |
| 2023-09-30 | 3.12 | $-4.60 | 0.00 |
| 2023-06-30 | 4.60 | $-6.05 | 0.00 |
| 2023-03-31 | 7.08 | $-7.18 | 0.00 |
| 2022-12-31 | 6.42 | $-9.01 | 0.00 |
| 2022-09-30 | 14.60 | $-8.52 | 0.00 |
| 2022-06-30 | 18.00 | $-9.09 | 0.00 |
| 2022-03-31 | 29.80 | $-9.21 | 0.00 |
| 2021-12-31 | 43.40 | $-8.59 | 0.00 |
| 2021-09-30 | 71.20 | $-8.81 | 0.00 |
| 2021-06-30 | 114.80 | $-8.26 | 0.00 |
| 2021-03-31 | 103.80 | $-8.66 | 0.00 |
| 2020-12-31 | 47.80 | $-8.31 | 0.00 |
| 2020-09-30 | 27.80 | $-8.71 | 0.00 |
| 2020-06-30 | 38.20 | $-8.72 | 0.00 |
| 2020-03-31 | 49.00 | $-7.41 | 0.00 |
| 2019-12-31 | 45.00 | $-8.04 | 0.00 |
| 2019-09-30 | 42.00 | $-7.14 | 0.00 |
| 2019-06-30 | 49.80 | $-6.38 | 0.00 |
| 2019-03-31 | 79.00 | $-7.31 | 0.00 |
| 2018-12-31 | 27.60 | $-6.17 | 0.00 |
| 2018-09-30 | 50.00 | $-6.97 | 0.00 |
| 2018-06-30 | 51.00 | $-7.90 | 0.00 |
| 2018-03-31 | 42.00 | $-8.38 | 0.00 |
| 2017-12-31 | 93.00 | $-8.93 | 0.00 |
| 2017-09-30 | 151.00 | $-8.51 | 0.00 |
| 2017-06-30 | 104.00 | $-7.12 | 0.00 |
| 2017-03-31 | 119.00 | $-6.32 | 0.00 |
| 2016-12-31 | 141.00 | $-5.75 | 0.00 |
| 2016-09-30 | 100.80 | $-7.63 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.102B | $0.004B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $24.733B | 27.19 |
| Tempus AI (TEM) | United States | $7.677B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $4.429B | 38.86 |
| Doximity (DOCS) | United States | $3.888B | 16.84 |
| IRhythm Holdings (IRTC) | United States | $3.724B | 0.00 |
| 10x Genomics (TXG) | United States | $2.973B | 0.00 |
| Privia Health (PRVA) | United States | $2.810B | 131.59 |
| Hinge Health (HNGE) | United States | $2.789B | 0.00 |
| Heartflow (HTFL) | United States | $2.311B | 0.00 |
| Omnicell (OMCL) | United States | $1.564B | 43.00 |
| Inspire Medical Systems (INSP) | United States | $1.555B | 20.94 |
| Enovis (ENOV) | United States | $1.405B | 7.40 |
| Butterfly Network (BFLY) | United States | $1.047B | 0.00 |
| Azenta (AZTA) | United States | $1.023B | 41.13 |
| Clover Health Investments (CLOV) | United States | $1.013B | 0.00 |
| Talkspace (TALK) | United States | $0.864B | 103.40 |
| Schrodinger (SDGR) | United States | $0.839B | 0.00 |
| Phreesia (PHR) | United States | $0.490B | 50.38 |
| Fulgent Genetics (FLGT) | United States | $0.429B | 0.00 |
| Standard BioTools (LAB) | United States | $0.345B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.322B | 0.00 |
| CapsoVision (CV) | United States | $0.311B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.279B | 0.00 |
| Claritev (CTEV) | United States | $0.269B | 0.00 |
| TruBridge (TBRG) | United States | $0.268B | 8.60 |
| Evolent Health (EVH) | United States | $0.260B | 0.00 |
| Carlsmed (CARL) | United States | $0.239B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.196B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.189B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 8.18 |
| Nyxoah SA (NYXH) | Belgium | $0.111B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.101B | 0.00 |
| American Well (AMWL) | United States | $0.086B | 0.00 |
| Outset Medical (OM) | United States | $0.077B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.058B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.052B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.034B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.018B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.009B | 0.00 |
| Zhongchao (ZCMD) | China | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.002B | 0.00 |
| PROFUSA (PFSA) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |